SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies

NEXT STORY
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
PREV STORY
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Dassault Systèmes: Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes

author_avatar
NASDAQ Market News

Embolotherapy Market Research Report by Product, by Disease Indication, by Procedure, by End User, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19

author_avatar
NASDAQ Market News

Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis

author_avatar
NASDAQ Market News